

LYNBROOK, N.Y., Sept. 19, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: [BSTC](#)), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Aegis Capital 2013 Healthcare Conference.

The presentation will take place on Thursday, September 26, 2013 at 4:00 p.m. EDT (1:00 p.m. PDT) at the Encore at Wynn hotel in Las Vegas, NV. This event will not be webcast.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed in Europe and approved in Canada.

Swedish Orphan Biovitrum AB has marketing rights for XIAPEX®

(the EU tradename for CCH) for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in

Japan

and Actelion Pharmaceuticals Ltd. has development and commercialization rights for XIAFLEX for these two indications in Canada

, Mexico

,

Brazil
and
Australia

. CCH is in clinical development for the treatment of several additional promising indications. The PDUFA date for XIAFLEX for Peyronie's disease is December 6

, 2013. Auxilium is also testing CCH for frozen shoulder syndrome and cellulite. Auxilium expects to initiate a Phase II trial of CCH for cellulite in the third quarter of this year and next stage trials of CCH for frozen shoulder syndrome in the fourth quarter of 2013. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase II trials. BioSpecifics expects top-line data from these trials in the second half of the year. For more information, please visit

www.biospecifics.com

.

SOURCE BioSpecifics Technologies Corp.

RELATED LINKS <http://www.biospecifics.com>